Intech Investment Management LLC increased its stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 54.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,138 shares of the company’s stock after purchasing an additional 5,319 shares during the period. Intech Investment Management LLC’s holdings in Guardant Health were worth $2,700,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of GH. The Manufacturers Life Insurance Company acquired a new position in shares of Guardant Health in the second quarter worth $208,592,000. William Blair Investment Management LLC purchased a new stake in shares of Guardant Health in the second quarter valued at $196,737,000. Orbimed Advisors LLC purchased a new stake in shares of Guardant Health in the first quarter valued at $40,199,000. Eagle Health Investments LP acquired a new stake in shares of Guardant Health during the second quarter valued at $45,112,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Guardant Health during the second quarter valued at $32,316,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.
Insiders Place Their Bets
In other Guardant Health news, CTO Darya Chudova sold 7,738 shares of Guardant Health stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total value of $1,377,364.00. Following the completion of the sale, the chief technology officer owned 70,635 shares in the company, valued at $12,573,030. The trade was a 9.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Terilyn J. Monroe sold 3,842 shares of the company’s stock in a transaction dated Wednesday, November 18th. The shares were sold at an average price of $142.41, for a total transaction of $547,139.22. Following the transaction, the insider directly owned 21,058 shares of the company’s stock, valued at approximately $2,998,869.78. This represents a 15.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 19,566 shares of company stock valued at $3,320,185. 5.60% of the stock is owned by corporate insiders.
Recent Guardant Health Headlines
These are some of the GH headlines that stood out recently:
- Positive Sentiment: Guardant launched Guardant Reveal Ultra in U.S. clinics, a molecular residual disease platform for solid tumors designed to detect cancer at a sensitivity of one part per million. The launch could expand the company’s testing offering and support future growth. Guardant Health launches Reveal Ultra
- Positive Sentiment: Stephens reaffirmed its “overweight” rating and set a $210 price target, signaling confidence in the stock’s prospects. Stephens stock recommendations
- Positive Sentiment: A recent report focused on raised guidance, which may bolster expectations for the company’s business outlook. What raised guidance means for shareholders
Wall Street Analyst Weigh In
GH has been the subject of a number of recent research reports. Stifel Nicolaus lifted their price objective on Guardant Health from $130.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, October 15th. Morgan Stanley upped their target price on shares of Guardant Health from $185.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, October 12th. UBS Group raised their price target on shares of Guardant Health from $175.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $191.48.
Guardant Health Stock Up 0.2%
Shares of Guardant Health stock opened at $145.83 on Friday. Guardant Health, Inc. has a fifty-two week low of $74.55 and a fifty-two week high of $191.05. The firm has a market cap of $19.73 billion, a PE ratio of -39.63 and a beta of 1.67. The business’s fifty day moving average is $167.08 and its two-hundred day moving average is $133.80.
Guardant Health (NASDAQ:GH – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.46. The business had revenue of $360.98 million for the quarter, compared to analyst estimates of $350.72 million. Guardant Health’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.74) EPS. Equities research analysts anticipate that Guardant Health, Inc. will post -3.28 EPS for the current year.
Guardant Health Profile
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
See Also
- Five stocks we like better than Guardant Health
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
